



DPC: 23/30468699 DC

**BSI Group Headquarters**

389 Chiswick High Road London W4 4AL

Tel: +44 (0)20 8996 9000

Fax: +44 (0)20 8996 7400

www.bsigroup.com

Date: 07 November 2023

Origin: International

**Latest date for receipt of comments: 31 December 2023**

Project No. 2023/00174

Responsible committee: TCI/100 Co-ordination of activities in textiles and clothing

Interested committees:

Title: Draft BS ISO 18184 Textiles - Determination of antiviral activity of textile products.

Please notify [admin.start@bsigroup.com](mailto:admin.start@bsigroup.com) if you are aware of any keywords that might assist in clarifying or identifying the standard or of the content of this standard:

- i) has any issues related to 3rd party IPR, patent or copyright
- ii) affects other national standard(s)
- iii) requires additional national guidance or information

**WARNING: THIS IS A DRAFT AND MUST NOT BE REGARDED OR USED AS A BRITISH STANDARD. THIS DRAFT IS NOT CURRENT BEYOND 31 December 2023**

This draft is issued to allow comments from interested parties; all comments will be given consideration prior to publication. No acknowledgement will normally be sent. **See overleaf for information on the submission of comments.**

No copying is allowed, in any form, without prior written permission from BSI except as permitted under the Copyright, Designs and Patent Act 1988 or for circulation within a nominating organization for briefing purposes. Electronic circulation is limited to dissemination by e-mail within such an organization by committee members.

Further copies of this draft may be purchased from BSI Shop <http://shop.bsigroup.com> or from BSI Customer Services, Tel: +44(0) 20 8996 9001 or email [cservices@bsigroup.com](mailto:cservices@bsigroup.com). British, International and foreign standards are also available from BSI Customer Services.

Information on the co-operating organizations represented on the committees referenced above may be obtained from <https://standardsdevelopment.bsigroup.com/>.

E-mail: [admin.start@bsigroup.com](mailto:admin.start@bsigroup.com)

## Introduction

This draft standard is based on national and international discussions. Your comments on this draft are invited and will assist in the preparation of the consequent standard.

For international standards, comments will be reviewed by the relevant UK national committee before sending the consensus UK vote and comments to the international committee, which will then decide appropriate action. If the international standard is approved, it is usual for the text to be published as a British Standard.

For national standards, comments will be reviewed by the relevant UK national committee and the resulting standards published as a British Standard.

## UK Vote

Please indicate whether you consider the UK should submit a negative (with supporting technical reasons) or positive vote on this draft. Please indicate if you are aware of any reason why this draft standard should not be published as a British Standard.

## Submission of Comments

- **Annotated drafts are not acceptable and will be rejected.**
- All comments should be submitted online at <https://standardsdevelopment.bsigroup.com/>. You will need to register in order to comment.

## Template for comments and secretariat observations

|                  |                        |
|------------------|------------------------|
| Date: xx/xx/20xx | Document: ISO/DIS xxxx |
|------------------|------------------------|

| 1  | 2                                          | (3)                          | 4               | 5                                                                                                                                  | (6)                                                                      | 7                                                  |
|----|--------------------------------------------|------------------------------|-----------------|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------|
| MB | Clause No./ Subclause No./Annex (e.g. 3.1) | Paragraph/ Figure/Table/Note | Type of comment | Comment (justification for change) by the MB                                                                                       | Proposed change by the MB                                                | Secretariat observations on each comment submitted |
|    | 3.1                                        | Definition 1                 | ed              | Definition is ambiguous and needs clarifying.                                                                                      | Amend to read '...so that the mains connector to which no connection...' |                                                    |
|    | 6.4                                        | Paragraph 2                  | te              | The use of the UV photometer as an alternative cannot be supported as serious problems have been encountered in its use in the UK. | Delete reference to UV photometer.                                       |                                                    |

# DRAFT INTERNATIONAL STANDARD

## ISO/DIS 18184

ISO/TC 38

Secretariat: SAC

Voting begins on:  
2023-11-07

Voting terminates on:  
2024-01-30

---

---

## Textiles — Determination of antiviral activity of textile products

*Textiles — Détermination de l'activité virucide de produits textiles*

ICS: 59.080.01

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENT AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.

This document is circulated as received from the committee secretariat.



Reference number  
ISO/DIS 18184:2023(E)  
**Documents**  
Document Sharing Hub  
© ISO 2023



## **COPYRIGHT PROTECTED DOCUMENT**

© ISO 2023

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

Page

|                                                                                                                     |           |
|---------------------------------------------------------------------------------------------------------------------|-----------|
| Foreword.....                                                                                                       | v         |
| Introduction.....                                                                                                   | vi        |
| <b>1 Scope.....</b>                                                                                                 | <b>1</b>  |
| <b>2 Normative references.....</b>                                                                                  | <b>1</b>  |
| <b>3 Terms and definitions.....</b>                                                                                 | <b>1</b>  |
| <b>4 Principle.....</b>                                                                                             | <b>3</b>  |
| <b>5 Example of virus and host cell.....</b>                                                                        | <b>3</b>  |
| <b>6 Warning.....</b>                                                                                               | <b>3</b>  |
| <b>7 Apparatus.....</b>                                                                                             | <b>3</b>  |
| <b>8 Sterilization of apparatus.....</b>                                                                            | <b>6</b>  |
| <b>9 Reagent and medium.....</b>                                                                                    | <b>7</b>  |
| <b>10 Preparation.....</b>                                                                                          | <b>12</b> |
| 10.1 Restoration of host cell from cryopreservation.....                                                            | 12        |
| 10.2 Subculture of host cell.....                                                                                   | 13        |
| 10.3 Cell culture for the infectious virus titre assay.....                                                         | 14        |
| 10.4 Preparation for test virus.....                                                                                | 14        |
| 10.4.1 General.....                                                                                                 | 14        |
| 10.4.2 Influenza virus.....                                                                                         | 14        |
| 10.4.3 Feline calicivirus.....                                                                                      | 15        |
| 10.4.4 Other viruses.....                                                                                           | 16        |
| 10.4.5 Infectivity titre of the test viruses.....                                                                   | 16        |
| 10.5 Preparation for test specimen.....                                                                             | 17        |
| 10.5.1 Control fabric.....                                                                                          | 17        |
| 10.5.2 Preparation of test specimens.....                                                                           | 17        |
| 10.5.3 Sterilization of control and test specimens.....                                                             | 17        |
| 10.6 Control test.....                                                                                              | 18        |
| 10.6.1 General.....                                                                                                 | 18        |
| 10.6.2 Verification of cytotoxicity by cell sensitivity to virus and the inactivation<br>of antiviral activity..... | 18        |
| <b>11 Test procedure.....</b>                                                                                       | <b>18</b> |
| 11.1 Preparation of control and test specimens.....                                                                 | 18        |
| 11.2 Deposit of virus to the control and test specimens.....                                                        | 19        |
| 11.3 Contacting time.....                                                                                           | 19        |
| 11.4 Wash-out of virus immediately after deposit.....                                                               | 19        |
| 11.5 Wash-out of virus after contacting time.....                                                                   | 19        |
| <b>12 Preparation of the series of the dilution for the virus suspension.....</b>                                   | <b>19</b> |
| <b>13 Determination of the infectious titre.....</b>                                                                | <b>20</b> |
| 13.1 Plaque assay.....                                                                                              | 20        |
| 13.2 TCID <sub>50</sub> method.....                                                                                 | 20        |
| 13.3 Testing method using specific pathogen free (SPF) embryonated hen's eggs.....                                  | 20        |
| <b>14 Calculation of infectivity titre.....</b>                                                                     | <b>20</b> |
| 14.1 Plaque assay.....                                                                                              | 20        |
| 14.2 TCID <sub>50</sub> method.....                                                                                 | 21        |
| 14.2.1 Behrens and Karber method.....                                                                               | 21        |
| 14.2.2 Example of calculation.....                                                                                  | 21        |
| 14.3 Test result.....                                                                                               | 23        |
| 14.3.1 Verification of this test.....                                                                               | 23        |
| 14.3.2 Calculation of antiviral activity value.....                                                                 | 23        |

|                              |                                                                                           |           |
|------------------------------|-------------------------------------------------------------------------------------------|-----------|
| <b>15</b>                    | <b>Example of test results</b> .....                                                      | <b>23</b> |
| <b>16</b>                    | <b>Judgement of antiviral efficacy</b> .....                                              | <b>24</b> |
| <b>17</b>                    | <b>Test report</b> .....                                                                  | <b>24</b> |
| <b>Annex A</b> (informative) | <b>Virus strains and host cells</b> .....                                                 | <b>25</b> |
| <b>Annex B</b> (informative) | <b>Test method for SARS-CoV-2</b> .....                                                   | <b>26</b> |
| <b>Annex C</b> (normative)   | <b>Infectivity titre test: Plaque assay</b> .....                                         | <b>36</b> |
| <b>Annex D</b> (normative)   | <b>Infectivity titre test: TCID<sub>50</sub> method</b> .....                             | <b>38</b> |
| <b>Annex E</b> (informative) | <b>Composition of media</b> .....                                                         | <b>39</b> |
| <b>Annex F</b> (informative) | <b>Additional examples of viruses and host cells</b> .....                                | <b>43</b> |
| <b>Annex G</b> (informative) | <b>Testing method using specific pathogen free (SPF) embryonated<br/>hen's eggs</b> ..... | <b>44</b> |
| <b>Annex H</b> (informative) | <b>Antiviral efficacy — Antiviral performance of the products</b> .....                   | <b>49</b> |
| <b>Annex I</b> (informative) | <b>Interlaboratory test result (1)</b> .....                                              | <b>50</b> |
| <b>Annex J</b> (informative) | <b>Interlaboratory test result (2)</b> .....                                              | <b>52</b> |
|                              | <b>Bibliography</b> .....                                                                 | <b>55</b> |

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

This document was prepared by Technical Committee ISO/TC 38, *Textile*.

This third edition cancels and replaces the second edition (ISO 18184:2019), which has been technically revised. The main changes compared to the previous edition are as follows:

- [14.3.2](#) Calculation of antiviral activity is updated
- [Annex B](#) is added for test method for SARS-CoV-2
- [Annex E, E.4](#) is added for the composition of DMEM medium
- [Annex F](#) is added for additional examples of the virus strain and host cells

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## Introduction

Recently, along with the global improvement in the level of living, consumers are showing the trend to seek healthcare or health protective products. Also, an increase in the people's interest for protection against epidemic diseases has been noted, as the overcrowded commuting train car where the commuters experience every day, the hospitals, nursing homes, etc.

Being supported by the processing technology of textile products to provide a high performance which has been highly developed recently, the health protective and hygiene relating products have been advancing into the market.

Because those products are relatively new and included the technical aspects out of textile technology, the testing methods have been developed by the individual producers to evaluate the product performance. That has resulted in inexistence of a unified test method, hindering for both consumers and producers a true explanation or understanding of those high functional products.

The antiviral product is one of those products and includes the technical fields of the textile technology and the biotechnology.

The demand to establish an international standard has been growing in the consumers, retailers, producers, etc. as the stakeholders in the market.

Antiviral textile products are textiles capable of reducing the number of infective virus particles that contact the surface of the textile. This document provides a quantitative test method to assess the antiviral performance of such products.

The data obtained in an objective manner by this document give the common knowledge to all the stake holders such as consumers, producers, retailers, etc. to understand the correct performance of the antiviral textile products.

There are two methods to quantify the number of infective virus, as infective virus titre in this document, which are the plaque method and the TCID<sub>50</sub> method. The method used can be selected by the experience and the convenience of each testing house. Any appropriate cellular system can be used and that the testing conditions when used should be reported.

See [Annexes I](#) and [J](#) for interlaboratory test results.

# Textiles — Determination of antiviral activity of textile products

**WARNING** — This document calls for use of the infectious viruses or substances/procedures that may be injurious to the health/environment if appropriate conditions are not observed. It refers only to technical suitability and does not absolve the user from legal obligations relating to health and safety/environment at any stage.

## 1 Scope

This document specifies testing methods for the determination of the antiviral activity of the textile products against viruses. Due to the individual sensitivities, the results of one test virus cannot be transposed to other viruses.

The textile products include woven and knitted fabrics, non-woven fabric, cotton, fibres, yarns, braids, feathers etc.

## 2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 105-F02, *Textiles — Tests for colour fastness — Part F02: Specification for cotton and viscose adjacent fabrics*

## 3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

### 3.1

#### **virus**

original biological entity which has a single type of nucleic acid (DNA or RNA), specific structure that opposes the virus to living organisms with a cellular structure (prokaryotes and eukaryotes), and reproduces from its genetic material by replication within the host cell, and leads to absolute intracellular parasitism

Note 1 to entry: The virion is the infectious viral particle.

### 3.2

#### **virus activity**

ability to replicate in the susceptible and permissive host cells

### 3.3

#### **antiviral activity**

property of any substance (chemical or otherwise) producing a modification of one of the elements of the virion structure which induces the latter's inability to replicate

Note 1 to entry: Property that reduces the viral activity, generally through morphological change or structural damage to the surface protein of the virus.

Note 2 to entry: It is not necessarily to imply that the change of antigenic response or the change of constituent element is the reduction of virus infectivity.

### 3.4

#### **antiviral chemicals**

inorganic or organic chemicals able to reduce *virus activity* ([3.2](#))

Note 1 to entry: The organic antiviral chemicals give the change to the surface protein of virus by the chemical adsorption. The inorganic metallic antiviral substances destroy or change the morphology of the virus by the extraction of hydrogen atom in the virus protein by OH radicals which are generated by the radical reaction.

### 3.5

#### **control fabric**

fabric used to verify the stability of the test virus on a textile fabric

Note 1 to entry: The fabrics before the antivirus treatment should be used as a control fabric with the same condition described in [3.5](#).

Note 2 to entry: When the fabrics before the antivirus treatment is not applicable, in Note 1, the 100 % cotton cloth described in ISO 105-F02 should be used without any chemical treatments such as the fluorescent bleach, etc.

### 3.6

#### **control test**

test to confirm that a test specimen does not affect the host cell

Note 1 to entry: This test is performed as same as actual test, but without virus.

### 3.7

#### **cytopathic effect**

##### **cytopathic effect (CPE) caused by virus**

effect appears as morphological change or destruction of the host cells as a result of the virus multiplication

### 3.8

#### **infectivity titre of virus**

number of infectious viral particles present per unit volume in a cell lysate or in viral suspension

### 3.9

#### **plaque**

area of lysed cells in a monolayer cell culture

### 3.10

#### **plaque forming units**

##### **PFU**

unit expressed as the concentration of the infectious virus per unit volume

### 3.11

#### **plaque assay**

assay to determine the infectivity *titre of virus* ([3.8](#)) from PFU by using the series of dilution

**3.12****TCID<sub>50</sub>**

50 % infectious dose of a wash-out virus suspension or the dilution of the virus suspension that induces a CPE in 50 % of cell culture units

Note 1 to entry: See [3.7](#).

**3.13****TCID<sub>50</sub> method**

assay to determine the *infectivity titre of virus* ([3.8](#)) from TCID<sub>50</sub> by using the series of dilution

**3.14****cytotoxicity**

morphological alteration of cells and/or their destruction or the reduction of their sensitivity to the multiplication of viruses induced by a product

**4 Principle**

The viruses are deposited onto a test and control specimen. After specific contact time, the remaining infectious virus is counted, and the reduction rate is calculated by the comparison between the antiviral product test specimen and the control specimen by common logarithm. There are two methods to quantify the infectious virus titre. One method is the plaque assay and the other is the TCID<sub>50</sub> method. The selection of the method depends on the convenience and experience of the testing organization.

**5 Example of virus and host cell**

Examples of species of viruses and host cells are shown in [Annex A](#), [Annex B](#) and [Annex F](#).

Other species of viruses and host cells can be used after appropriate validations, as the important virus may differ depending on target application. If the other species are used, the name of the species and the specific reason for their use shall be included in the test report.

NOTE Reference viruses are listed in EN 14476 and EN 14675.

**6 Warning**

Handling and manipulation of viruses and host cells which are potentially hazardous requires a high degree of technical competence and may be subject to current national legislation and regulations. Appropriate safety precautions should be observed with due consideration given to country-specific regulations. Only personal trained in biological techniques should carry out such tests. Appropriate practices for disinfection, sterilization and personal hygiene must be strictly observed.

**7 Apparatus**

**7.1 High pressure steam sterilizer: Autoclave**, capable of operating at a temperature of  $(121 \pm 2) ^\circ\text{C}$  (See ISO 20743, 5.28).

**7.2 Dry heat sterilizer: Ovens**, capable of operating at a temperature of  $(180 \pm 2) ^\circ\text{C}$  and  $(160 \pm 2) ^\circ\text{C}$ .

**7.3 Measuring flask**, with capacity of 1 l.

**7.4 Balance**, with the available range of 0,01 g to 100 g with accuracy of 1,0 % (see ISO 20743, 5.13).

**7.5 Pipette**, of various capacities with accuracy of 10 % of the nominal volume.

**7.6 Washing machine.**

**7.7 Pipetter**, capable of mounting the glass or plastic pipettes.

**7.8 Micropipette**, having the most suitable volume for each use, with a tip made of glass or plastic, and with a tolerance of 0,5 % or less.

**7.9 Water bath**, capable of maintaining at a temperature of  $(37 \pm 1) ^\circ\text{C}$ ,  $(50 \pm 1) ^\circ\text{C}$  and  $(56 \pm 1) ^\circ\text{C}$ .

**7.10 Vortex®<sup>1)</sup>-type mixer**, used for microbial testing.

**7.11 Freezer**, capable of operating at a temperature of  $(-80 \pm 2) ^\circ\text{C}$  or  $(-20 \pm 2) ^\circ\text{C}$ .

**7.12 Liquid nitrogen bath**, for the preservation at approximately  $-196 ^\circ\text{C}$ .

**7.13 Membrane filtration device**, with a pore size of  $0,22 \mu\text{m}$ .

**7.14 Refrigerator**, capable of operating at a temperature between  $2 ^\circ\text{C}$  and  $8 ^\circ\text{C}$ .

**7.15 pH meter**, having an inaccuracy of calibration  $\pm 0,1$  pH units at  $(20 \pm 1) ^\circ\text{C}$  (See ISO 20743).

**7.16 Inverted microscope**, capable of being used for cultured cells observation.

**7.17 Tweezers**, capable of being sterilized.

**7.18 Centrifuge**, capable of being operated at a temperature of  $(4 \pm 2) ^\circ\text{C}$ , and relative centrifugal force of approximately 1 000 g.

**7.19 Biological safety cabinet**, class II.

**7.20 Vial container**, with a capacity of 30 ml and closed with the screw cap. The gasket is made of perfluoroethylene or silicone and the cap is made of polypropylene.

**7.21 96 wells microplate with the gamma radiation sterilization**, for TCID<sub>50</sub> method.

96 wells microplates with other sterilization finish may be used after appropriate validation for the growth of cells. See [Figure 1](#).

---

1) This information is given for the convenience of users of this document and does not constitute an endorsement of ISO by this product.




**Figure 1 — 96 wells microplate for TCID<sub>50</sub> method**

**7.22 6 wells plastic plate with the gamma radiation sterilization, for plaque assay.**

6 wells plates with other sterilization finish may be used after appropriate validation for the growth of cells. See [Figure 2](#).



**Figure 2 — 6 wells plastic plate for plaque assay**

**7.23 Flask, for cell culture use with the gamma radiation sterilization finish, with an adherent type, a cell culture area of 75 cm<sup>2</sup> and with the vent cap. The vent cap can exchange abacterial air through 0,2 µm filter. See [Figure 3](#).**

Flask with other sterilization finish may be used after appropriate validation for the growth of cells.



**Figure 3 — Flask for cell culture use**

**7.24 CO<sub>2</sub> incubator**, capable of maintaining an atmosphere with 5 % CO<sub>2</sub>, at a temperature of  $(34 \pm 1) ^\circ\text{C}$  and  $(37 \pm 1) ^\circ\text{C}$ .

**7.25 Incubator**, capable of maintaining at a temperature of  $(25 \pm 1) ^\circ\text{C}$ ,  $(35 \pm 1) ^\circ\text{C}$  and  $(37 \pm 1) ^\circ\text{C}$ .

**7.26 Centrifuge tube**.

**7.27 Culture container**.

**7.28 Test tube**.

**7.29 Beaker**.

**7.30 Glass rod**, with approximately 18 mm in diameter.

**7.31 Mixer**.

## **8 Sterilization of apparatus**

Sterilize all apparatus which come in contact with the cells, the chemicals, or test specimen. The sterilization method shall be used by high pressure steam or dry heat method.

- High pressure steam sterilization: by an autoclave ([7.1](#)) at a temperature of  $121 ^\circ\text{C}$  and a pressure of 103 kPa for 15 min.
- Dry-heat sterilization: by a dry heat sterilizer ([7.2](#)) at a temperature of  $180 ^\circ\text{C}$  for 30 min or  $160 ^\circ\text{C}$  for 2 h.

In case of plastics products, heat-resistant plastics products or sterilization finish plastics products may be used.

## 9 Reagent and medium

All reagents shall have the quality suitable for virological needs, i.e. free of toxic substances for testing microorganisms. Some of the media are available in the market.

**9.1 Water**, which shall be analytical-grade water for microbiological media preparation, which is ion-exchanged and/or freshly distilled and/or ultra-filtered and/or filtered with RO (reverse osmosis).

**9.2 Eagle's minimum essential medium (EMEM), Roswell Park Memorial Institute medium (RPMI)**, available in the market. The composition is described in [Annex E](#). If there are any components missing from the composition, add them according to the composition table.

### 9.3 7,5 % sodium bicarbonate solution.

Prepare the solution according to the method 1 or method 2., and mix well just before using.

#### 9.3.1 Method 1:

**9.3.1.1** Sterilize sodium bicarbonate, 75 g in autoclave in a culture container ([7.27](#)) with a cap closed tightly.

**9.3.1.2** Water ([9.1](#)) is also sterilized by autoclave.

**9.3.1.3** Dissolve sodium bicarbonate in the sterilized water ([9.3.1.2](#)) of 1 000 ml well.

#### 9.3.2 Method 2:

**9.3.2.1** Prepare 7,5 % sodium bicarbonate solution by dissolving 75 g of sodium bicarbonate in 1 000 ml of water ([9.1](#)).

**9.3.2.2** Sterilize the solution by using 0,22 µm membrane filter.

### 9.4 Formaldehyde solution.

Prepare a formaldehyde solution at the concentration of 3,7 % in water as follows,

**9.4.1** Prepare 100 ml of a 37 % formaldehyde solution.

**9.4.2** Add 900 ml of water ([9.1](#)) into the solution of [9.4.1](#).

The other solution for cell fixation may be used after appropriate validation for the cell fixation.

### 9.5 Methylene blue solution.

**9.5.1** Prepare a measuring flask ([7.3](#)) of 1 l, then, put the following materials in the flask ([7.3](#)):

- Water ([9.1](#)), 1 000 ml;
- Methylene blue, 0,375 g;
- 1 mol/l sodium hydroxide solutions 62,5 µl.

**9.5.2** Dissolve and mix well.

## 9.6 Inactivated fetal bovine serum (FBS)

**9.6.1** Put the freeze-dried cryopreserved fetal bovine serum in a package in the water bath (7.9) at a temperature of 37 °C and keep it until defrosting.

**9.6.2** Then, raise the temperature of the water bath to 56 °C and keep it for 30 min to inactivate.

**9.6.3** Divide it into several tubes. Put them in the freezer (7.11) at a temperature lower than –20 °C until use for testing.

**9.6.4** Just before use, put it in the water bath at a temperature of 37 °C and keep it until defrosting.

## 9.7 Growth medium.

### 9.7.1 Influenza virus and feline calicivirus

**9.7.1.1** Prepare a measuring flask (7.3) of 1 l, and put the following materials into the flask (7.3):

- Water (9.1), 800 ml;
- Kanamycin sulfate, 60 mg;
- Eagle's minimum essential medium (EMEM) (E.2), 9,53 g, or RPMI 1640 medium (E.3), 10,4 g.

**9.7.1.2** Dissolve and mix well and make up whole solution to 1 000 ml by water.

**9.7.1.3** Sterilize the mixed solution from 9.7.2 by using 0,22 µm filter (7.13).

**9.7.1.4** Add 15 ml of 7,5 % sodium bicarbonate solution (9.3) and 100 ml of the inactivated fetal bovine serum (9.6) in the solution from 9.7.1.3.

### 9.7.2 Other viruses

In case of SARS-CoV-2, prepare the growth medium according to Annex B. In case of additional example of viruses described in Annex F, select the appropriate growth medium for host cells of each virus.

## 9.8 Maintenance medium.

### 9.8.1 Influenza virus and feline calicivirus

**9.8.1.1** Prepare a measuring flask (7.3) of 1 l, then, put the following materials in the flask:

- Water (9.1), 800 ml;
- Kanamycin sulfate, 60 mg;
- Eagle's minimum essential medium, 9,53 g.

**9.8.1.2** Dissolve them well, then, make up the whole amount to 1 000 ml by adding water (9.1).

**9.8.1.3** Sterilize the mix solution from 9.8.1.2 by using the filter (7.13) with a pore size of 0,22 µm.

**9.8.1.4** Add 15 ml of 7,5 % sodium bicarbonate solution (9.3) in the mix solution of 9.8.1.3.

### 9.8.2 Other viruses

In case of SARS-CoV-2, prepare the maintenance medium according to [Annex B](#). In case of additional example of viruses described in [Annex F](#), select the appropriate maintenance medium for host cells of each virus.

### 9.9 Double concentration of the maintenance medium.

**9.9.1** Prepare a measuring flask ([7.3](#)) of 1 l, then, put the following materials in the flask ([7.3](#)):

- Water ([9.1](#)), 800 ml;
- Kanamycin sulfate, 120 mg;
- Eagle's minimum essential medium, 19,06 g.

**9.9.2** Dissolve them well, then, make up the whole amount to 1 000 ml by adding water.

**9.9.3** Sterilize the mixed solution from [9.9.2](#) by using the filter ([7.13](#)) with a pore size of 0,22 µm.

### 9.10 0,01 mol/l phosphate buffered saline (PBS (-)).

**9.10.1** Prepare a measuring flask ([7.3](#)) of 1 l, then, put the following materials in the flask ([7.3](#)):

- Water ([9.1](#)), 800 ml;
- Sodium chloride, 8 g;
- Potassium chloride, 0,2 g;
- Disodium hydrogen phosphate 12 H<sub>2</sub>O, 2,9 g;
- Potassium dihydrogen phosphate, 0,2 g.

**9.10.2** Dissolve the materials of [9.10.1](#) and mix well and add water by making up the whole amount to 1 000 ml and dissolve well.

**9.10.3** Then, transfer the mix solution of [9.10.2](#) into a culture container ([7.27](#)), then sterilize the mix solution by using an autoclave ([7.1](#)) at a temperature of 121 °C for 15 min.

### 9.11 Trypsin derived from beef pancreas and (PBS (-)) mix solution.

**9.11.1** Prepare a beaker ([7.29](#)), then, put the following materials in the beaker:

- 0,01 mol/l phosphate buffered saline (PBS (-)) ([9.10](#)), 100 ml;
- Trypsin derived from beef pancreas, 1,0 g.

**9.11.2** Dissolve the materials of [9.11.1](#) and mix well by using mixer ([7.31](#)) for 2 h.

**9.11.3** Then, sterilize the mix solution [9.11.2](#) by using the filter ([7.13](#)) with a pore size of 0,22 µm.

The divided mix solution in tubes that are not used immediately are preserved in the freezer ([7.11](#)) at a temperature of lower than -80 °C until usage for testing.

**9.11.4** Prepare a test tube (7.28) and put the following solutions in the test tube (7.28):

- 0,01 mol/l phosphate buffered saline PBS (-) (9.10), 9 ml;
- Trypsin derived from beef pancreas and PBS (-) mix solution of 9.11.3, 1 ml.

**9.11.5** Dissolve the solutions of 9.11.4 and mix them well.

**9.11.6** Divide the mix solution of 9.11.5 in test tubes (7.28) and preserve in the freezer (7.11) at a temperature of lower than -20 °C until usage for testing.

**9.11.7** Just before using, put the mix solution in test tube of 9.11.6 in the water bath (7.9) at a temperature of 37 °C and keep the mix solution in the tube until defrosting.

## **9.12 Trypsin and ethylenediaminetetraacetic acid (EDTA) solution.**

**9.12.1** Prepare a measuring flask (7.3) of 1 l, then, put the following materials in the measuring flask (7.3):

- 0,01 mol/l phosphate buffered saline PBS (-) (9.10), 800 ml;
- Trypsin, 2,5 g;
- Kanamycin sulfate, 0,1 g;
- Streptomycin sulfate, 0,1 g;
- Amphotericin B, 2 mg;
- Ethylenediaminetetraacetic acid (EDTA), 0,014 mol.

**9.12.2** Dissolve the materials of 9.12.1 and mix well. Add 0,01 mol/l phosphate buffered saline (PBS (-)) (9.10) into the mix solution of 9.12.1 and make up the total amount to 1 000 ml.

**9.12.3** Then, sterilize the mix solution of 9.12.2 by using the filter (7.13) with a pore size of 0,22 µm.

**9.12.4** Divide the mix solution of 9.12.3 in test tubes (7.28) and preserve in the freezer (7.11) at a temperature lower than -20 °C until use for testing.

**9.12.5** Before use, place the test tube of 9.12.4 in a water bath (7.9) at 37 °C until fully defrosted.

Trypsin EDTA solution is available in the market. The products with the different components from 9.12.1, may be used after proper validation.

## **9.13 Diethylaminoethyl (DEAE)-dextran solution.**

**9.13.1** Prepare a measuring flask (7.3) of 1 l, then, put the following materials in the measuring flask (7.3):

- Water (9.1), 1 000 ml;
- Diethylaminoethyl (DEAE)-dextran, 20 g.

**9.13.2** Dissolve the materials of 9.13.1 and mix well. Add water (9.1) and make up the total amount to 1 000 ml.

**9.13.3** Sterilize the mix solution of 9.13.2 by using the filter (7.13) with a pore size of 0,22 µm.

## 9.14 Agar medium preparation.

### 9.14.1 Influenza virus and feline calicivirus

#### 9.14.1.1 Liquid A.

**9.14.1.1.1** Prepare a sterilized culture container ([7.27](#)) of 1 l, then, put the following materials in the culture container:

- Double concentration of maintenance medium ([9.9](#)) 1 000 ml;
- DEAE-dextran solution ([9.13](#)) 10 ml;
- 7,5 % sodium bicarbonate solution ([9.3](#)) 40 ml.

Dissolve the materials of [9.14.1](#) and mix well.

**9.14.1.1.2** Only for the plaque assay of the influenza virus test, add 3,0 ml of the trypsin derived from beef pancreas and (PBS (-)) mix solution ([9.11](#)).

**9.14.1.1.3** Put the mix solution of [9.14.1.1](#) and [9.14.1.2](#) in the water bath ([7.9](#)) at a temperature of 37 °C and keep it until using.

#### 9.14.1.2 Liquid B.

**9.14.1.2.1** Prepare a culture container ([7.27](#)) of 2 l, then, put the following materials in the culture container ([7.27](#)):

- Water ([9.1](#)), 1 000 ml;
- Cell culture agar, 15 g.

Dissolve the materials of the 9.14.2.1 and mix well.

**9.14.1.2.2** Sterilize the mix solution of 9.14.2.1 by using autoclave ([7.1](#)) at a temperature of 121 °C and a pressure of 103 kPa for 15 min.

**9.14.1.2.3** Put the mix solution of 9.14.2.2 in the water bath ([7.9](#)) at a temperature of 50 °C and keep it until using.

**9.14.1.3** Mix liquid A and liquid B at 1:1 (vol/vol).

### 9.14.2 Other viruses

In case of SARS-CoV-2, prepared the agar medium according to [Annex B](#). In case of additional examples of viruses described in [Annex E](#), select the appropriate agar medium for each virus.

## 9.15 Wash-out solution

### 9.15.1 General

The wash-out solution is used for the wash-out of the virus from the test and control specimens and for suppression of anti-virus activity of the chemicals treated on the anti-virus textile product and prepared as the following.

Other wash-out solution may be used after appropriate validation.